Is Ro-1-9213 Safe in Breastfeeding

Question

I am a breastfeeding mother and i want to know if it is safe to use Ro-1-9213? Is Ro-1-9213 safe for nursing mother and child? Does Ro-1-9213 extracts into breast milk? Does Ro-1-9213 has any long term or short term side effects on infants? Can Ro-1-9213 influence milk supply or can Ro-1-9213 decrease milk supply in lactating mothers?

Ro-1-9213 lactation summary

DrLact safety Score for Ro-1-9213 is 1 out of 8 which is considered Safe as per our analyses.
A safety Score of 1 indicates that usage of Ro-1-9213 is mostly safe during lactation for breastfed baby.
Our study of different scientific research also indicates that Ro-1-9213 does not cause any serious side effects in breastfeeding mothers.
Most of scientific studies and research papers declaring usage of Ro-1-9213 safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About Ro-1-9213 usage in lactation

American Academy of Pediatrics: Maternal Medication Usually Compatible With Breastfeeding.

Answer by DrLact: About Ro-1-9213 usage in lactation

Limited information from an old study indicates that maternal doses of Ro-1-9213 of 1 gram daily produce moderate levels in milk. If Ro-1-9213 is required by the mother, it is not a reason to discontinue breastfeeding, especially if the infant is older than 2 months. Exclusively breastfed infants should be monitored if this drug is used during lactation, possibly including measurement of serum levels to rule out toxicity if there is a concern.

Ro-1-9213 Side Effects in Breastfeeding

No adverse effects were noted in 5 in breastfed infants (ages not stated) whose mothers were taking oral Ro-1-9213 250 mg 4 times daily.[1] Ro-1-9213 was used as part of multi-drug regimens to treat 5 women with multidrug-resistant tuberculosis, 4 throughout pregnancy and postpartum and the other postpartum only. The infants were breastfed (extent and duration not stated). At age 1.25, 1.8, 3.9, 4.6 and 5.5 years, the children were developing normally except for a mild speech delay in one and hyperactivity in another.[4]